Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors

Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors

Publication date: Jun 12, 2020

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that combines EGFR with TGF?. Based on preclinical data, this dual targeted, bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

Concepts Keywords
Anal Canal Magnetic resonance imaging
Antibodies KRAS
Antibody Cetuximab
Antigen Pembrolizumab
ATC Lung cancer
Biopsy Breakthrough therapy
Breast Clinical medicine
Breastfeeding Merck
Carcinoma Cancer treatments
Cetuximab HCV RNA
Cohort Eligible positive hepatitis
Colorectal Carcinoma Patient tumor
Computed Tomography Tumors
Cooperative Group Measurable disease
Corticosteroids Stable colorectal carcinoma
Cytologically Tumor
EGFR Magnetic resonance imaging
GBM Tomography
Glioblastoma Antibodies
HBsAg MRI
HBV
HCV
Hepatitis
Hepatocellular Carcinoma
Histologically
HIV
Hypersensitivity Reaction
Immune Checkpoint Inhibitor
Immunodeficiency
Immunosuppressive Medication
Infection
Intranasal
Investigational Drug
KRAS
Lesion
Lung
Magnetic Resonance Imaging
Maximum Tolerated Dose
Micrometer
Microsatellite
MRI
Murine
Mutation
Paraffin
Physician
Polymerase Chain Reaction
Prednisone
Primary Tumor
Protocol
RAS
Refractory
RNA
Solid Tumor
Squamous
Squamous Carcinoma
Steroids
Synergistic
Thyroid
TNBC
Topical
Toxicity
Tumor
Uveal Melanoma
Virus
Wild Type

Semantics

Type Source Name
disease MESH Carcinoma
disease MESH infection
pathway KEGG Hepatitis C
disease MESH hepatitis C
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
pathway KEGG Hepatitis B
disease MESH hepatitis B
drug DRUGBANK Prednisone
drug DRUGBANK Cetuximab
disease MESH hypersensitivity
pathway KEGG Pancreatic cancer
disease MESH Pancreatic cancer
drug DRUGBANK Timonacic
disease MESH Anaplastic thyroid cancer
pathway KEGG Hepatocellular carcinoma
disease MESH Hepatocellular carcinoma
disease MESH Epithelial ovarian cancer
pathway KEGG Gastric cancer
disease MESH Gastric cancer
disease MESH Glioblastoma
disease MESH Uveal melanoma
disease MESH Chordoma
disease MESH Triple negative breast cancer
disease MESH colorectal carcinoma
drug DRUGBANK Rasagiline
disease MESH Head and neck squamous cell carcinoma
disease MESH biopsy
disease MESH Tumors
drug DRUGBANK Pembrolizumab

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *